Existing and Developing Preclinical Models for Neurofibromatosis Type 1−Related Cutaneous Neurofibromas
Journal of Investigative Dermatology · 2023
DOI: 10.1016/j.jid.2023.01.042 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Investigative Dermatology, 2023. Verfasst von Verena Staedtke und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: vstaedt1@jhmi.edu. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Neurofibroma, Skin Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, School of Medicine, Johns Hopkins University, Neurofibromatosis Therapeutic Acceleration Program.
Abstract (Originalsprache)
Neurofibromatosis type 1 (NF1) is caused by a nonfunctional copy of the NF1 tumor suppressor gene that predisposes patients to the development of cutaneous neurofibromas (cNFs), the skin tumor that is the hallmark of this condition. Innumerable benign cNFs, each appearing by an independent somatic inactivation of the remaining functional NF1 allele, form in nearly all patients with NF1. One of the limitations in developing a treatment for cNFs is an incomplete understanding of the underlying pathophysiology and limitations in experimental modeling. Recent advances in preclinical in vitro and in vivo modeling have substantially enhanced our understanding of cNF biology and created unprecedented opportunities for therapeutic discovery. We discuss the current state of cNF preclinical in vitro and in vivo model systems, including two- and three-dimensional cell cultures, organoids, genetically engineered mice, patient-derived xenografts, and porcine models. We highlight the models' relationship to human cNFs and how they can be used to gain insight into cNF development and therapeutic discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: vstaedt1@jhmi.edu.
- Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France.
- Department of Dermatology, UT Southwestern Medical Center, Dallas, Texas, USA.
- SPARK Program in Translational Research, Stanford University School of Medicine, Stanford, California, USA; Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, USA.
- Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
- School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
Förderung
- NINDS NIH HHS
- School of Medicine, Johns Hopkins University
- Neurofibromatosis Therapeutic Acceleration Program
- U.S. Department of Defense
- Johns Hopkins University
Zitieren
APA
Staedtke, V., Topilko, P., Le, L. Q., Grimes, K., Largaespada, D. A., Cagan, R. L., Steensma, M. R., Stemmer-Rachamimov, A., Blakeley, J. O., Rhodes, S. D., Ly, I., Romo, C. G., Lee, S. Y., & Serra, E. (2023). Existing and Developing Preclinical Models for Neurofibromatosis Type 1−Related Cutaneous Neurofibromas. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2023.01.042
Vancouver
Staedtke V, Topilko P, Le LQ, Grimes K, Largaespada DA, Cagan RL, et al. Existing and Developing Preclinical Models for Neurofibromatosis Type 1−Related Cutaneous Neurofibromas. Journal of Investigative Dermatology. 2023. doi:10.1016/j.jid.2023.01.042
BibTeX
@article{Staedtke2023,
author = {Staedtke, Verena and Topilko, Piotr and Le, Lu Q and Grimes, Kevin and Largaespada, David A and Cagan, Ross L and Steensma, Matthew R and Stemmer-Rachamimov, Anat and Blakeley, Jaishri O and Rhodes, Steven D and Ly, Ina and Romo, Carlos G and Lee, Sang Y and Serra, Eduard},
title = {Existing and Developing Preclinical Models for Neurofibromatosis Type 1−Related Cutaneous Neurofibromas},
journal = {Journal of Investigative Dermatology},
year = {2023},
doi = {10.1016/j.jid.2023.01.042}
}
EUVIMED